Latest Conference Articles

A Texas study revealed that the implementation of electronic patient management solutions resulted in reduced call back times for symptom-related calls as well as reduced hospitalizations.

KRAS mutational status and geographical region were associated with time on treatment (TOT), and body mass index (BMI) and age were linked with overall survival (OS) in patients with metastatic colorectal cancer mCRC) being treated with second-line cetuximab (Erbitux) after irinotecan or oxaliplatin-based regimens.

Cabozantinib exposure was not a predictor of progression-free survival was related to high rate of palmar-plantar plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma.

This year, there were many takeaways from the American Society of Clinical Oncology Annual Meeting that oncology nurses can incorporate into their practice.

Learn how to approach palliative care discussions with both physicians and patients.

Men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer who are being treated with radium-223 (Xofigo) plus enzalutamide (Xtandi) can reduce their risk of fractures with the use of bone-protecting agents.

The second-generation 4-1BB bi-specific CAR T-cell therapy was efficacious and safe in treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Sacituzumab govitecan, an antibody drug conjugate, maintained survival and response benefits over chemotherapy regimens.

Survival rates were similar between the 2 drugs, but acalabrutinib had fewer adverse events.

Previously treated patients with non-small cell lung cancer tended to have better responses with Retevmo than they did with prior treatments.

Adjuvant carboplatin and paclitaxel after standard cisplatin-based chemoradiation did not demonstrate improved overall survival or progression-free survival in patients with locally advanced cervical cancer.

Pralsetinib elicited promising responses and tolerability in patients with RET fusion-positive non-small cell lung cancer (NSCLC), including those who were not eligible for platinum-based therapy.

Patients with BRCA1/2-mutant, early HER2-negative breast cancer at a high risk of recurrence saw a clinically meaningful benefit 1 year after standard of care when treated with olaparib.

States without Medicaid expansion tended to have poorer cancer outcomes than states with higher income limits on eligibility, according to recent research.

When in-person classes on central venous catheter care were limited due to the COVID-19 pandemic, educational videos became even more important.

Knowing your patient’s beliefs and goals is key to providing ethical cancer care.

Nurse practitioners are more valuable than ever in the world of cancer care.

Factors such as being younger in age, having more comorbidities, and more prior cancer treatments all contribute to higher levels of sleep disturbance in patients with gastrointestinal cancers.

In particular, patients reported improved knowledge in survivorship/surveillance and brain fog following the 6-week program.

When patients rely on lip-reading to communicate, mask mandates have major effects on their care.

The “cheat sheet” assisted advanced practice providers using a step-by-step guide that is updated frequently to allow for the most up-to-date information.

A recent study analyzed the benefits and work-related stressors of end-of-life care.

Due to the COVID-19 pandemic, many patients’ and survivors’ care has changed, but one nurse and her team sought to make this population more comfortable and safe during these times with virtual visits.

Early research showed an improvement in provider recommendations of care for patients with breast cancer based on eight guideline metrics.

Survivors of cancer go through coping during the first year after treatment and require specific resources. But these were limited due to the pandemic resulting in survivors self-coping with known mechanisms.

The current scale often used to measure nurse quality of life may be missing some key factors, according to recent research.

The use of a smartphone mobile app showed that patients with cancer had higher adherence to oral chemotherapy regimens, especially when it came to safely monitoring chemotherapy toxicity and symptoms in real time.

A walking program dramatically increased the number of steps walked by patients being treated for hematologic malignancies.